Swiss study of Canadian made Ebola vaccine resumes

The Guinean village of Meliandou is widely believed to have been the home of the current Ebola outbreak's Patient Zero. AP

Helen Branswell The Canadian Press A trial in Switzerland of a Canadian-made Ebola vaccine resumed this week after being suspended over concerns about an unexpected side-effect reported by some volunteers.

And while the Geneva-based trial of the rVSV-ZEBOV got back on track, researchers at Oxford University began testing another Ebola vaccine, made by the Janssen Pharmaceutical Companies of Johnson & Johnson.

The Janssen vaccine joins rVSV-ZEBOV, which is being developed by Merck and NewLink Genetics, and a vaccine being developed by GSK (formerly GlaxoSmithKline) in the race to provide the world with a licensed Ebola preventative.